Plaque Rupture and Thrombosis
Davide Capodanno, Full Professor of Cardiology at the University of Catania, shared on X:
“Plaque rupture with thrombosis drives ACS, and thin-cap fibroatheroma is the archetypal high-risk plaque. There are consistent features of vulnerability across imaging modalities (large plaque burden, small MLA, TCFA, high LCBI, positive remodelling, etc.), with risk increasing when multiple features coexist. Yet absolute event rates remain low, consistent with pathology data showing most plaque ruptures are clinically silent.
So should we prophylactically stent high-risk plaques? According to this Viewpoint, completed trials (PROSPECT ABSORB, PREVENT) suggest no durable reduction in death or MI versus optimal medical therapy—benefits are limited to fewer revascularisations, at the cost of many unnecessary PCIs. With modern medical therapy, a wait-and-see strategy appears safe, avoiding most interventions without adverse consequences. For now, data favor surveillance and aggressive medical therapy over preventive PCI.
READ THE VIEWPOINT HERE.

Stay updated with Hemostasis Today.
-
Feb 13, 2026, 06:01Heghine Khachatryan: Privileged To Participate In the ASH MMENA Partner Societies Leadership Meeting
-
Feb 12, 2026, 16:36Tagreed Alkaltham: Tranexamic Acid in PBM
-
Feb 12, 2026, 16:35Paul Lambis Announces Maria Hadjidemetriou as a Speaker at Cyprus Diaspora Forum
-
Feb 12, 2026, 16:34Rahul Bhargava: Breaking Myths About Bone Marrow Transplant
-
Feb 12, 2026, 16:29Arun V J: Can You Be A Doctor And Still Be Stupid?
-
Feb 12, 2026, 16:26Changing the Narrative Around PPH – End Postpartum Hemorrhage
-
Feb 12, 2026, 16:20Mahesan Subramaniam: The Protective Switch in Brain Immune Cells Could Slow Alzheimer’s Disease
-
Feb 12, 2026, 16:13Lale Tokgözoğlu: Top 10 Dyslipidemia Papers of 2025
-
Feb 12, 2026, 16:10Neelam Mohan: Breaking Down Anemia from Causes and Testing to Treatment and Prevention